Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3552W HIGH $4.00
Volume
3.60 M
Value Traded
355.14 K
Short % Float
4.64%
+12.45%Week
+16.55%1 Month
-19.22%3 Month
-57.5%6 Month
-83.73%5 Year
-83.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
27.54 M
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
18.82 M
Total Shares
56.35 M
Float Shares
45.81 M
Insiders
18.71%
Institutions
14.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BEAT Catalyst Timeline
Dated clinical, regulatory and corporate events for Heartbeam, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Heartbeam, Inc.
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How BEAT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Heartbeam, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BEAT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cruickshank TimOfficer (CFO) | Buy | 31,250 72,230 held | $0.80 | 04/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BEAT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BEAT for Q2 2026. | ||||
BEAT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BEAT ranks across every disease it competes in
Competitive Position is a premium feature
See how BEAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBEAT News
BEAT▲ +50.5%on this news
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment
HeartBeam has been granted FDA Breakthrough Device Designation for its innovative heart attack assessment technology. This designation is expected to expedite the development and review process, potentially leading to improved patient care. The recognition highlights the device's potential to address critical needs in cardiac diagnostics.
Read more →BEAT▲ +7%on this news
HeartBeam, Inc. Letter to Shareholders
HeartBeam, Inc. is shifting its focus towards heart attack detection, redirecting resources from its current arrhythmia product. The company emphasizes the potential of its 3D ECG technology to identify heart attacks earlier. Recent clinical studies have shown promising progress, and HeartBeam plans to pursue FDA clearance for its 12-lead patch through strategic partnerships.
Read more →BEAT▼ -15.3%on this news
HeartBeam Reports Second Quarter 2026 Results
HeartBeam, Inc. reported its Q2 2026 results, highlighting operational advancements in cardiac care technology. The company successfully enrolled patients in key studies ahead of schedule and launched its ECG products for arrhythmia assessment. Despite a net loss of $5 million, HeartBeam's cash position improved significantly, and it continues to engage with the FDA for future indications.
Read more →BEATHeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time
HeartBeam has announced it will host a conference call to discuss its financial results for the second quarter of 2026. The call is scheduled for August 13, 2026, at 4:30 p.m. Eastern Time. This event aims to provide insights into the company's performance and future outlook.
Read more →BEATHeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device
HeartBeam has received a new U.S. patent that enhances the capabilities of its cable-free ECG device. This patent focuses on expanding the acoustic sensing and fluid monitoring features, indicating a significant advancement in their technology. The development could improve patient monitoring and diagnostics in cardiac care.
Read more →BEAT▲ +14.8%on this news
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
HeartBeam has successfully completed enrollment for its pilot study on heart attack detection ahead of the planned schedule. This study aims to evaluate the effectiveness of their technology in identifying heart attacks. The early completion of enrollment may expedite the research process and provide valuable insights sooner.
Read more →BEAT▼ -7.7%on this newsshared move
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
HeartBeam has announced a strategic shift aimed at accelerating the global adoption of its ambulatory ECG signal platform. The company is also undergoing a leadership transition to support this initiative. Specific details regarding the changes and their expected impact on the business were not provided in the article.
Read more →BEATHeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
HeartBeam, Inc. announced a peer-reviewed study published in JACC: Advances, demonstrating that its ECG device can accurately assess heart attack risk. The study involved 212 patients and showed that combining ECG data with clinical risk factors achieved an AUC of 86.5%. This advancement supports HeartBeam's plans for heart attack detection, addressing a significant market need.
Read more →BEATHeartBeam Announces Proposed Public Offering
HeartBeam, Inc. has announced a proposed public offering of its common stock, which will be underwritten and is intended to fund the commercialization of its FDA-cleared 12-lead synthesized ECG system. The company plans to utilize the net proceeds to enhance its cardiac technology offerings, including an extended-wear patch and AI capabilities. However, the completion of the offering is uncertain and subject to market conditions.
Read more →BEAT▼ -8.5%on this news
HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study
HeartBeam, Inc. has initiated its ALIGN-ACS pilot study, enrolling the first patients to evaluate its HeartBeam System for heart attack detection. Conducted at the University Clinical Center of Serbia, the study aims to compare the HeartBeam device's performance with standard ECGs in emergency settings. This pilot is a crucial step towards expanding the device's indications and improving timely cardiac care.
Read more →BEATHeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market
HeartBeam, Inc. has announced a commercial partnership with ClearCardio, marking its first commercial customer. This collaboration will integrate HeartBeam's innovative 12-lead ECG technology into ClearCardio's cardiac prevention program, enhancing patient care and monitoring. The partnership is structured to ensure a smooth rollout and supports HeartBeam's long-term growth strategy in preventive cardiology.
Read more →BEATHeartBeam Appoints Bryan Humbarger as Chief Commercial Officer
HeartBeam, Inc. has appointed Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In his new role, Humbarger will spearhead the company's commercial strategy and lead initiatives for the limited launch of the HeartBeam System, aimed at enhancing cardiac care. His extensive experience in the MedTech sector is expected to accelerate HeartBeam's growth and market presence.
Read more →BEAT▲ +12.8%on this news
HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
HeartBeam, Inc. will attend the JP Morgan 2026 Annual Healthcare Conference from January 12-15, 2026. The company's CEO and CFO will meet with investors to discuss their recently FDA-cleared 12-lead ECG synthesis software. This technology allows patients to obtain ECG readings from home, enhancing cardiac care convenience. A limited commercial launch is planned for Q1 2026.
Read more →BEAT▲ +36.8%on this news· ran to +122% by day 3
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
HeartBeam, Inc. has received FDA 510(k) clearance for its novel cable-free 12-lead ECG synthesis software, enabling at-home arrhythmia assessments. This technology captures heart signals in three dimensions, providing patients with timely ECG readings. The company plans a limited U.S. launch in Q1 2026, aiming to revolutionize cardiac care and improve heart attack detection.
Read more →BEATHeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
HeartBeam, Inc. has appointed CEO Robert Eno to its Board of Directors, expanding the Board to nine members. This decision reflects the company's commitment to innovation as it advances towards the commercialization of its 3D ECG technology. Eno, who has over 30 years of experience in the medical technology sector, will provide critical expertise in sales and market strategies. The appointment comes after HeartBeam received FDA clearance for its technology and is preparing for further developments in cardiac health management.
Read more →BEATHeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common Stock
HeartBeam, Inc. announced the exercise of the underwriter's over-allotment option for its public offering, resulting in additional gross proceeds of approximately $1.5 million. This brings the total gross proceeds from the offering to about $11.5 million. The funding will support the company's strategic plan, focusing on growth milestones and commercial readiness. MDB Capital acted as the underwriter for the offering, which closed on February 25, 2025.
Read more →BEATsettings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a
HeartBeam, Inc. has appointed Dr. Michael R. Jaff to its board of directors, bringing in a highly respected vascular physician with extensive clinical and industry experience. Dr. Jaff's background includes roles as Chief Medical Officer at Boston Scientific and professor at Harvard Medical School. His expertise is expected to guide HeartBeam's technological advancements and regulatory approvals. The company's innovative 3D-vector electrocardiogram technology aims to enhance remote cardiac diagnostics for patients.
Read more →BEATDocument HeartBeam Appoints Ken Nelson and Mark Strome to the Board of Directors Accomplished Medical Technology Leader and Veteran Investor Bring Strategic Experience and Vision to Board
HeartBeam, Inc. has appointed Ken Nelson and Mark Strome to its board of directors, effective June 5, 2023. Ken Nelson brings over 20 years of experience in digital health and medical devices, while Mark Strome has over 40 years in investment management. Their expertise is expected to support HeartBeam's goals in advancing its innovative cardiac technology and positioning the company for future growth.
Read more →BEAT▲ +12.7%on this news
Document HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG
HeartBeam, Inc. has completed a $25 million capital raise, enhancing its financial position as it aims to lead in ambulatory vectorcardiography. With net proceeds of $23.2 million, HeartBeam intends to develop its HeartBeam AIMIGo system and pursue FDA 510(k) clearances, targeting commercialization in 2024. The company plans to adjust its strategic focus to prioritize clinical trials and build partnerships in the market. Financial guidance suggests no significant commercial revenue for 2023 as the company executes its strategic initiatives.
Read more →BEATBreakthrough Cardiac Health Monitoring Always by your side 1 Disclaimers This presentation contains forward - looking statements . All statements other than statements of historical fact contained in this presentation, i
HeartBeam is introducing a breakthrough portable cardiac health monitoring solution that aims to replicate the diagnostic capabilities of a 12-lead ECG. The device utilizes vectorcardiography technology, which could significantly enhance the early detection of heart conditions and improve management. Despite the innovative approach, the HeartBeam platform has not yet been evaluated or approved by the FDA for clinical use. The company has outlined a regulatory strategy to establish its technology as the gold standard in ambulatory heart monitoring.
Read more →About Heartbeam, Inc.
Headquarters2118 WALSH AVE., SUITE 210, SANTA CLARA, CA, 95050
Founded2015
BIOPHARMAWATCH ELITE PLUS
Trade the next BEAT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime